Daniel Temko

Daniel Temko

Auto-generated profile, based on publicly available information

Daniel Temko

Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Nature Ecology & Evolution
Verified
Journal Article
Closed access
PDF file
WCWilliam Cross
William Cross
MKMichal Kovac
Michal Kovac
VMVille Mustonen
Ville Mustonen
DTDaniel Temko
Daniel Temko
HDHayley Davis
Hayley Davis
ITIan P. M. Tomlinson
Ian P. M. Tomlinson

10 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DTDaniel Temko
Daniel Temko
ITIan P. M. Tomlinson
Ian P. M. Tomlinson
SSSimone Severini
Simone Severini
BSBenjamin Schuster-Böckler
Benjamin Schuster-Böckler
TGTrevor Graham
Trevor Graham
Epidemiological evidence has long associated environmental mutagens with increased cancer risk. However, links between specific mutation-causing processes and the acquisition of individual driver mutations have remained obscure. Here we have used public cancer sequencing data from 11,336 cancers of various types to infer the independent effects of mutation and selection on the set of driver mutations in a cancer type. First, we detect associations between a range of mutational processes, including those linked to smoking, ageing, APOBEC and DNA mismatch repair (MMR) and the presence of key driver mutations across cancer types. Second, we quantify differential selection between well-known alternative driver mutations, including differences in selection between distinct mutant residues in the same gene. These results show that while mutational processes have a large role in determining which driver mutations are present in a cancer, the role of selection frequently dominates.

21 November 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
LSLaura E. Stevens
Laura E. Stevens
GPGuillermo Peluffo
Guillermo Peluffo
XQXintao Qiu
Xintao Qiu
DTDaniel Temko
Daniel Temko
AFAnne Fassl
Anne Fassl
KPKornelia Polyak
Kornelia Polyak
Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment. In breast cancer, CD44+CD24− cells possess stem cell-like features and contribute to disease progression, and we previously described a CD44+CD24−pSTAT3+ breast cancer cell subpopulation that is dependent on JAK2/STAT3 signaling. Here we report that CD44+CD24− cells are the most frequent cell type in IBC and are commonly pSTAT3+. Combination of JAK2/STAT3 inhibition with paclitaxel decreased IBC xenograft growth more than either agent alone. IBC cell lines resistant to paclitaxel and doxorubicin were developed and characterized to mimic therapeutic resistance in patients. Multi-omic profiling of parental and resistant cells revealed enrichment of genes associated with lineage identity and inflammation in chemotherapy-resistant derivatives. Integrated pSTAT3 chromatin immunoprecipitation sequencing and RNA sequencing (RNA-seq) analyses showed pSTAT3 regulates genes related to inflammation and epithelial-to-mesenchymal transition (EMT) in resistant cells, as well as PDE4A, a cAMP-specific phosphodiesterase. Metabolomic characterization identified elevated cAMP signaling and CREB as a candidate therapeutic target in IBC. Investigation of cellular dynamics and heterogeneity at the single cell level during chemotherapy and acquired resistance by CyTOF and single cell RNA-seq identified mechanisms of resistance including a shift from luminal to basal/mesenchymal cell states through selection for rare preexisting subpopulations or an acquired change. Finally, combination treatment with paclitaxel and JAK2/STAT3 inhibition prevented the emergence of the mesenchymal chemo-resistant subpopulation. These results provide mechanistic rational for combination of chemotherapy with inhibition of JAK2/STAT3 signaling as a more effective therapeutic strategy in IBC. Significance: Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors.

2 June 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ZLZheqi Li
Zheqi Li
GPGuillermo Peluffo
Guillermo Peluffo
LSLaura E. Stevens
Laura E. Stevens
XQXintao Qiu
Xintao Qiu
MSMarco Seehawer
Marco Seehawer
KPKornelia Polyak
Kornelia Polyak
Basal breast cancer is a subtype with a poor prognosis in need of more effective therapeutic approaches. Here we describe a unique role for the KDM4C histone lysine demethylase in KDM4C-amplified basal breast cancers, where KDM4C inhibition reshapes chromatin and transcriptomic landscapes without substantial alterations of its canonical substrates, trimethylated histone H3 lysine 9 (H3K9me3) and lysine 36 (H3K36me3). Rather, KDM4C loss causes proteolytic cleavage of histone H3 mediated by cathepsin L (CTSL), resulting in decreased glutamate–cysteine ligase expression and increased reactive oxygen species. CTSL is recruited to the chromatin by the grainyhead-like 2 (GRHL2) transcription factor that is methylated at lysine 453 following KDM4C inhibition, triggering CTSL histone clipping activity. Deletion of CTSL rescued KDM4-loss-mediated tumor suppression. Our study reveals a function for KDM4C that connects cellular redox regulation and chromatin remodeling.

31 May 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DTDaniel Temko
Daniel Temko
YCYu-Kang Cheng
Yu-Kang Cheng
KPKornelia Polyak
Kornelia Polyak
FMFranziska Michor
Franziska Michor
Recent debate has concentrated on the contribution of bad luck to cancer development. The tight correlation between the number of tissue-specific stem cell divisions and cancer risk of the same tissue suggests that bad luck has an important role to play in tumor development, but the full extent of this contribution remains an open question. Improved understanding of the interplay between extrinsic and intrinsic factors at the molecular level is one promising route to identifying the limits on extrinsic control of tumor initiation, which is highly relevant to cancer prevention. Here, we use a simple mathematical model to show that recent data on the variation in numbers of breast epithelial cells with progenitor features due to pregnancy are sufficient to explain the known protective effect of full-term pregnancy in early adulthood for estrogen receptor–positive (ER+) breast cancer later in life. Our work provides a mechanism for this previously ill-understood effect and illuminates the complex influence of extrinsic factors at the molecular level in breast cancer. These findings represent an important contribution to the ongoing research into the role of bad luck in human tumorigenesis. Cancer Res; 77(11); 2800–9. ©2017 AACR.

12 June 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
DTDaniel Temko
Daniel Temko
ITIan Pm Tomlinson
Ian Pm Tomlinson
SSSimone Severini
Simone Severini
BSBenjamin Schuster-Böckler
Benjamin Schuster-Böckler
TGTrevor Graham
Trevor Graham
Epidemiological evidence has long associated environmental mutagens with increased cancer risk. However, links between specific mutation-causing processes and the acquisition of individual driver mutations have remained obscure. Here we have used public cancer sequencing data to infer the independent effects of mutation and selection on driver mutation complement. First, we detect associations between a range of mutational processes, including those linked to smoking, ageing, APOBEC and DNA mismatch repair (MMR) and the presence of key driver mutations across cancer types. Second, we quantify differential selection between well-known alternative driver mutations, including differences in selection between distinct mutant residues in the same gene. These results show that while mutational processes play a large role in determining which driver mutations are present in a cancer, the role of selection frequently dominates.